Skeletal cell model to screen anti-diabetic compounds

Details Skeletal cell model to screen anti-diabetic compounds Skeletal cell model to screen anti-diabetic compounds

2006-05-30

2006-05-30

Davis, Ruth A. (Department: 1651)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of regulating cell metabolism or physiology

C435S373000, C435S325000, C435S354000

Reexamination Certificate

active

07052910

ABSTRACT:
The present invention relates to the development of insulin resistant skeletal muscle cell culture model useful for the screening of compounds that enhance insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation required against type II diabetes.

REFERENCES:
patent: 5998386 (1999-12-01), Feldman
patent: 2002/0197596 (2002-12-01), Cooper et al.
Kumar et al., “Development of insulin non-responsive in skeletal muscle cell line”, FASEB Journal, Mar. 2001, vol. 15, No. 4, p. A207.
Sarabia et al., “Glucose uptake in human and animal muscle cells in culture”, Biochem Cell Biol. 1990, 68 (2), 536-542, abstract.
Saad et al., “Insulin and Dexamethasone Regulate Insulin Receptors, Insulin Recptor Substrate-1, and Phosphatidyinositol 3-Kinase in Fao Hepatoma Cells”, Endocrinology, 1995, vol. 136, No. 4, p. 1579-1588.
U.S. Appl. No. 60/280,584, filed Mar. 30, 2001.

Affiliated with

Also associated with

Rating

Skeletal cell model to screen anti-diabetic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Skeletal cell model to screen anti-diabetic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Skeletal cell model to screen anti-diabetic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3588421